全文获取类型
收费全文 | 113940篇 |
免费 | 31335篇 |
国内免费 | 1107篇 |
专业分类
耳鼻咽喉 | 2564篇 |
儿科学 | 3340篇 |
妇产科学 | 2969篇 |
基础医学 | 4753篇 |
口腔科学 | 5207篇 |
临床医学 | 28176篇 |
内科学 | 27226篇 |
皮肤病学 | 3690篇 |
神经病学 | 13904篇 |
特种医学 | 3886篇 |
外科学 | 19452篇 |
综合类 | 334篇 |
现状与发展 | 40篇 |
一般理论 | 36篇 |
预防医学 | 16031篇 |
眼科学 | 2347篇 |
药学 | 2262篇 |
中国医学 | 26篇 |
肿瘤学 | 10139篇 |
出版年
2024年 | 758篇 |
2023年 | 5206篇 |
2022年 | 1386篇 |
2021年 | 3350篇 |
2020年 | 5646篇 |
2019年 | 2662篇 |
2018年 | 7502篇 |
2017年 | 7776篇 |
2016年 | 8362篇 |
2015年 | 8484篇 |
2014年 | 11095篇 |
2013年 | 13087篇 |
2012年 | 5377篇 |
2011年 | 5244篇 |
2010年 | 7646篇 |
2009年 | 9822篇 |
2008年 | 4698篇 |
2007年 | 3729篇 |
2006年 | 4742篇 |
2005年 | 3125篇 |
2004年 | 2379篇 |
2003年 | 1952篇 |
2002年 | 1778篇 |
2001年 | 1883篇 |
2000年 | 1156篇 |
1999年 | 1719篇 |
1998年 | 2171篇 |
1997年 | 1951篇 |
1996年 | 1987篇 |
1995年 | 1731篇 |
1994年 | 1114篇 |
1993年 | 932篇 |
1992年 | 755篇 |
1991年 | 640篇 |
1990年 | 515篇 |
1989年 | 518篇 |
1988年 | 512篇 |
1987年 | 388篇 |
1986年 | 366篇 |
1985年 | 300篇 |
1984年 | 259篇 |
1983年 | 305篇 |
1982年 | 236篇 |
1981年 | 202篇 |
1980年 | 125篇 |
1978年 | 122篇 |
1977年 | 116篇 |
1976年 | 86篇 |
1974年 | 78篇 |
1972年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
131.
132.
133.
134.
135.
Bo Jørgensen MD ; Gitte Juel Friis PhD ; Finn Gottrup MD DMSci 《Wound repair and regeneration》2006,14(3):233-239
Wound pain is a serious problem for elderly patients suffering from chronic leg ulcers, and it may lead to reduced wound healing rates and reduced quality of life. Biatain-Ibu Non-adhesive (Coloplast A/S), a new pain-reducing moist wound healing dressing containing ibuprofen was tested for pain reduction, safety, and efficacy on 10+2 patients in a single-blinded crossover study against Biatain Non-adhesive (Coloplast A/S). Pain was measured with a Numeric Box Scale before, during, and after dressing change. Quality of life was measured using the World Health Organization-5 Well-Being Index. Dressing moist wound healing properties such as absorption capacity and leakage were tested together with assessment of wound exudate and blood plasma content of ibuprofen. Use of the Biatain-Ibu foam dressing correlated with a decrease in pain intensity scores from 7 in the run-in period to approximately 2.5 in the Biatain-Ibu treatment phase. Quality of life measures were improved which together with the reduced pain could contribute to faster wound healing. The moist wound healing properties of Biatain-Ibu were similar to that of the Biatain Non-adhesive and ulcer size was reduced by 24% during the treatment period. Neither side effects nor systemic plasma concentrations of ibuprofen were observed. These data indicate that Biatain-Ibu could reduce persistent and temporary wound pain, increase Quality of life, was found safe to use, and had excellent moist wound healing properties. 相似文献
136.
137.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
138.
139.
140.
Alexander Stoff MD ; Angel A. Rivera PhD ; N. S. Banerjee PhD ; J. Michael Mathis PhD ; Antonio Espinosa-de-los-Monteros MD ; Long P. Le PhD ; Jorge I. De la Torre MD ; Luis O. Vasconez MD ; Thomas R. Broker PhD ; Dirk F. Richter MD ; Mariam A. Stoff-Khalili MD ; David T. Curiel MD PhD 《Wound repair and regeneration》2006,14(5):608-617
Genetically modified keratinocytes and fibroblasts are suitable for delivery of therapeutic genes capable of modifying the wound healing process. However, efficient gene delivery is a prerequisite for successful gene therapy of wounds. Whereas adenoviral vectors (Ads) exhibit superior levels of in vivo gene transfer, their transductional efficiency to cells resident within wounds may nonetheless be suboptimal, due to deficiency of the primary adenovirus receptor, coxsackie-adenovirus receptor (CAR). We explored CAR-independent transduction to fibroblasts and keratinocytes using a panel of CAR-independent fiber-modified Ads to determine enhancement of infectivity. These fiber-modified adenoviral vectors included Ad 3 knob (Ad5/3), canine Ad serotype 2 knob (Ad5CAV-2), RGD (Ad5.RGD), polylysine (Ad5.pK7), or both RGD and polylysine (Ad5.RGD.pK7). To evaluate whether transduction efficiencies of the fiber-modified adenoviral vectors correlated with the expression of their putative receptors on keratinocytes and fibroblasts, we analyzed the mRNA levels of CAR, alpha upsilon integrin, syndecan-1, and glypican-1 using quantitative polymerase chain reaction. Analysis of luciferase and green fluorescent protein transgene expression showed superior transduction efficiency of Ad5.pK7 in keratinocytes and Ad5.RGD.pK7 in fibroblasts. mRNA expression of alpha upsilon integrin, syndecan-1 and glypican-1 was significantly higher in primary fibroblasts than CAR. In keratinocytes, syndecan-1 expression was significantly higher than all the other receptors tested. Significant infectivity enhancement was achieved in keratinocytes and fibroblasts using fiber-modified adenoviral vectors. These strategies to enhance infectivity may help to achieve higher clinical efficacy of wound gene therapy. 相似文献